OncoTherapy Science Stock Hits Day Low of JPY 26 Amid Price Pressure

OncoTherapy Science, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock dropping by 12.9%. The stock reached an intraday low of JPY 26.00, reflecting ongoing challenges in its financial performance. Over the past year, OncoTherapy has generated a modest return of 3.85%, which starkly contrasts with the Japan Nikkei 225's impressive gain of 73.13% during the same period. The company's market position remains precarious, as indicated by a negative EBITDA of Rs. -816 crore and a return on equity (ROE) of -46.51%. Additionally, OncoTherapy's financial metrics reveal a concerning trend, with raw material costs surging by 172.84% year-over-year and a low debtors turnover ratio of 8.72 times. Despite a year-to-date performance of 35.0%, the stock's long-term trajectory shows a decline of 92.56% over the past decade, highlighting the challenges the company faces in a competitive market.